United States: Amgen v. Sandoz BPCIA Dispute Heads To The Federal Circuit

Last Updated: April 28 2015
Article by Aron Fischer and Nathan Monroe-Yavneh

After a series of preliminary skirmishes, the first full-fledged litigation under the Biologics Price Reduction and Innovation Act is Amgen's lawsuit against Sandoz concerning Sandoz's Zarxio, a biosimilar version of Amgen's blockbuster biologic Neupogen.  Last month, the district court for the Northern District of California denied Amgen's motion for a preliminary injunction and granted judgment as a matter of law to Sandoz on Amgen's claims that Sandoz had violated the BPCIA by refusing to participate in the statutory pre-litigation "patent dance" and by serving a notice of commercial marketing before the license application was approved.

The parties in Amgen v. Sandoz  have now taken their case to the Federal Circuit on an expedited schedule.  Over the past month, both parties, as well as the district court and the Federal Circuit, have participated in a flurry of briefing and scheduling activity that seems poised to lead to an interim decision by the Federal Circuit early next month and a decision on the appeal by the summer or early fall.

The Expedited Schedule

Following the March 19 decision on Amgen's motion for a preliminary injunction, the parties and courts acted quickly to bring the appeal to the Federal Circuit.  On March 25, Judge Seeborg entered partial judgment for Sandoz, and Amgen filed a notice of appeal to the Federal Circuit the same day. The Federal Circuit quickly approved an expedited schedule that will see briefing completed by the end of the month. Amgen filed its opening brief on April 3, Sandoz filed its opposition on April 21, and Amgen's reply is due on April 28. The Federal Circuit has scheduled oral argument for June 3.

Meanwhile, an important (and potentially prophetic) interim decision on an injunction pending appeal is even closer at hand.  On April 15, the district court denied Amgen's motion for an injunction pending appeal, stating that "[w]hile Amgen raises significant and novel legal questions as to the merits of its case, as noted in the Court's prior order, its tenuous and highly contingent showing of irreparable harm forecloses injunctive relief."  Sandoz agreed to refrain from launching Zarxio until the earlier of May 11 or a decision by the Federal Circuit on Amgen's application for an injunction pending appeal, but has not agreed to stay off the market pending ultimate resolution of the appeal.

On April 17, Amgen moved in the Federal Circuit for relief pending appeal.  The parties agreed on a briefing schedule for the motion under which briefing would conclude by April 28, and the Federal Circuit quickly approved the schedule.  The court's prompt attention to the motion suggests that it is poised to decide the motion by May 11, the date until which Sandoz has agreed to stay off the market.

Arguments of the Parties and Amici

In the Federal Circuit briefing, Amgen and its amici argue that the district court's holding that the BPCIA "patent dance" procedures are optional undermines the basic purpose and structure of the statute.  In its opening brief, Amgen contends in particular that Judge Seeborg made four errors. First, Amgen argues that the district court erred in holding that Sandoz was not required to give Amgen a copy of its aBLA and its manufacturing process information, despite the BPCIA's language stating that a biosimilar applicant "shall provide" this information. Second, Amgen argues that the district court erred in holding that Sandoz had properly given notice of commercial marketing, since the BPCIA refers to a "licensed" biological product. Third, Amgen challenges the court's holding that the sole remedy for a BPCIA violation is a declaratory judgment for patent infringement, as opposed to a cause of action under federal or state law. Fourth, Amgen contends that the court erred by denying its motion for a preliminary injunction to compel Sandoz to comply with the BPCIA, "as properly construed."

Two major biotechnology companies, AbbVie and Janssen Biotech 1, as well the Biotechnology Industry Organization (BIO), filed amicus briefs with the Federal Circuit supporting reversal of Judge Seeborg's decision. The amici contend that the BPCIA's intricate "patent dance" procedures were intended to be followed, and argue that the district court's decision, by permitting the biosimilar applicant to bypass them, would upset the statute's carefully calibrated balance of interests.  As the AbbVie brief puts it, "It is impossible to read subsection [42 U.S.C. 262](l) from beginning to end and conclude that Congress went through all of that effort, provided all of those details, and considered all of the potential alternatives, only to conclude by saying in (l)(9): 'but do whatever you want.'"

In its opposition brief, Sandoz presents a different view of the BPCIA.  According to Sandoz, the BPCIA procedures are merely "procedural means to a substantive goal: resolving patent disputes so that non-infringing biosimilars can be available to patients as expeditiously as possible."  As such, Sandoz contends that biosimilar applicants do not need to follow the statutory procedures when they do not find it in their interest to do so.  Sandoz argues that by describing the BPCIA procedures as steps the parties "shall" undertake, Congress did not mean that the parties would be in violation of the law if they failed to undertake them, but rather that the parties "shall" participate in the patent-exchange procedures if they wish the "patent-exchange process to continue."  Furthermore, Sandoz contends, the statutory limitations on declaratory judgment actions are the sole consequence for failing to participate in the statutory procedures, so that even if not participating in the statutory procedures were a violation, there could be no additional judicially enforceable remedies.  Sandoz's position is supported by amicus curiae the Generic Pharmaceutical Association.  The GPhA brief argues that Congress intended the BPCIA "patent dance" to be "non-mandatory" and that requiring participation in the statutory procedures would lead to absurd results in cases where the innovator did not have any relevant patents.

In sum, with the Federal Circuit briefing nearly complete and an expedited schedule in place, a decision on the BPCIA "patent dance" procedures is on the horizon.  Although it always remains a possibility that the court could decide the appeal on narrow grounds, the Federal Circuit's coming decision is likely to provide some guidance on the BPCIA's dispute resolution procedures.


1 Patterson Belknap represents Janssen Biotech in its litigation with Celltrion and Hospira and in its amicus brief to the Federal Circuit supporting Amgen.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.